No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months by Willenheimer, Ronnie et al.
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Primary research
No effects on myocardial ischaemia in patients with stable
ischaemic heart disease after treatment with ramipril for
6 months
Ronnie Willenheimer, Steen Juul-Möller, Lennart Forslund and Leif Erhardt
Department of Cardiology, Malmö University Hospital, Lund University, Malmö, Sweden
Correspondence: Dr Ronnie Willenheimer, Department of Cardiology, Malmö University Hospital, S-205 02 Malmö, Sweden. Tel: +46 40 33 10 00;
Fax: +46 40 33 62 09; e-mail: ronnie.willenheimer@medforsk.mas.lu.se
Introduction
ACE may play a key role in the pathophysiology of
ischaemic heart disease, through its effects on levels of
angiotensin II, bradykinin and nitric oxide (NO).
Angiotensin II is a potent vasoconstrictor and induces
growth of myocardial and vascular cells, as well as induc-
ing increased deposition of collagen, causing vascular and
myocardial remodelling [1]. Conversely, NO inhibits prolif-
eration of vascular smooth muscle cells [2–4], and is nec-
essary for relaxation of the vasculature [4]. ACE inhibitors
may counteract the negative effects of angiotensin II, and
potentiate the beneficial effects of bradykinin and NO [5],
with consequent anti-ischaemic effects in the myocardium.
Indeed, several studies [6–10] have shown beneficial
effects of ACE inhibitors on ischaemia-related clinical
events, as well as direct anti-ischaemic effects in patients
with left ventricular systolic dysfunction. However, some
studies failed to demonstrate anti-ischaemic effects of
ACE inhibitor treatment [11,12], and reports of anti-
ischaemic effects of ACE inhibition in patients with
ischaemic heart disease and preserved left ventricular sys-
tolic function are somewhat scarce [13–16].
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The present study (the Low-dose Ramipril Against Myocar-
dial Ischaemia [LORAMI] study) was performed in order to
investigate the effects on myocardial ischaemia of a 6-
month intervention with 1.25 mg/day and 5 mg/day of the
ACE inhibitor ramipril in comparison with placebo, in
patients with stable ischaemic heart disease and preserved
left ventricular systolic function. The main efficacy variables
were duration of STD, total ischaemic burden (total area of
significant STD) and maximum STD on 48-h ambulatory
electrocardiography. The use of a low dose of ramipril
(1.25 mg/day) was based on prior findings in experimental
[17] and clinical [18] studies of possible beneficial effects
of low doses of ramipril that do not affect blood pressure.
Methods
Patients
Patients (aged 30–80 years) with stable symptomatic or
asymptomatic ischaemic heart disease (on the basis of a
history of myocardial infarction or typical angina pectoris,
with positive exercise test and/or a pathological coronary
angiogram) were examined by ambulatory electrocardio-
graphy. Those who showed at least 10 min STD of at least
0.1 mV during 48 h were eligible for inclusion, irrespective
of the presence of symptoms. Patients who had sympto-
matic heart failure and/or left ventricular systolic dysfunction
(which constitutes an indication for ACE inhibition), a con-
traindication to ACE inhibitor treatment, ACE inhibitor treat-
ment within 3 months before study initiation, continuing
digitalis treatment, non-sinus rhythm, an inconclusive ambu-
latory electrocardiogram or unstable angina were excluded.
All patients gave written informed consent to participate the
study, which was approved by the local ethics committee.
Intervention
After a 2-week, single-blind, placebo run-in period,
patients were randomly assigned on a 1:1:1 basis to
receive double-blind treatment with ramipril 5 mg once
daily or 1.25 mg once daily, or placebo, in addition to the
baseline medication. During the first week of randomized
treatment, patients were titrated to target doses of the
study medication. The randomized treatment was given for
24 weeks.
Ambulatory electrocardiography
Baseline ambulatory electrocardiography was performed
before the run-in period. It was repeated after 1 month of
double-blind treatment and at the study end, while the
patients were still on randomized treatment. The analysis
was performed using a Del Mar Avionics Strata Scan
ECG analyser for STD (Del Mar Avionics, Irvine, CA,
USA). Electrocardiography was done using tape
recorders (Dynacord Model 423; Del Mar Avionics), with a
60-min cassette electrocardiography-tape and x, y and z
orthogonal vector leads. Ischaemic STD was defined as at
least 1 min of at least 0.1 mV depressions, as measured
between a baseline measure point between P and Q on
electrocardiography and another measure point 64 ms
after the junction point. The ST-slope had to be horizontal
or descending.
STD was quantified both as duration (min per 48 h) and
as the area of STD, defined as the area between the elec-
trocardiography baseline and the actual ST level during
STD for the whole duration (ischaemic burden, mV/48 h).
During each of the six 24-h periods, the patient was asked
to perform 6 min physical exercise at the maximal level that
he/she could manage. All physical activities were regis-
tered by the patient in a specially designed diary with
written instructions for physical activity. The patients were
asked to repeat this physical activity during each of the
24-h electrocardiography monitoring periods, and to main-
tain a level of routine daily activity throughout the investi-
gational periods.
Blood pressure measurement
Blood pressure was measured at baseline (ie at the time
of randomization). It was repeated after the titration period
(after 1 week of randomized treatment), after 12 weeks of
randomized treatment and at study end. Blood pressure
was measured in the supine position in the right arm after
at least 10 min rest using a standard sphygmomanometer.
The supine systolic blood pressure is accounted for in the
following analysis.
Sample size calculation
We assumed a difference between each of the two
ramipril groups and placebo of 0.2 in the relative reduction
of total ischaemic burden, and a standard deviation of 0.5.
Using an a level of 0.025 for each test, 120 evaluable
patients per group were required in order to obtain 80%
power to detect a difference between a specific active
group and placebo. This resulted in a power of approxi-
mately 70% to detect a difference between both active
treatment groups and placebo, and a power of approxi-
mately 90% to detect a difference between at least one of
the active treatment groups and placebo.
Statistical analysis
Efficacy was defined as the relative decrease in the
respective efficacy variables from baseline to study end.
The efficacy analyses were performed as analyses of
covariance, adjusting for history of myocardial infarction
and anti-ischaemic medication. Differences in adverse
events were tested with a c2 test. In general, comparisons
were made between ramipril 5 mg/day and placebo, as
well as between ramipril 1.25 mg/day and placebo.
Changes in the primary efficacy variables were related to
the systolic blood pressure changes during the study by
analysis of covariance, without adjustment for history of
myocardial infarction or anti-ischaemic medication. Two-
tailed  P < 0.05 was considered statistically significant.c
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Results
A total of 389 patients were randomized: 133 in the ramipril
5 mg/day group; 133 in the ramipril 1.25 mg/day group;
and 123 in the placebo group. All of these patients were
included in the safety analyses. Forty-two patients discontin-
ued prematurely, and thus 347 patients completed the trial:
118 in the ramipril 5 mg/day group; 116 in the ramipril
1.25 mg/day group; and 113 in the placebo placebo. These
patients were included in the efficacy analyses.
There were no significant differences between the groups
in terms of frequency of discontinuations. The reasons for
discontinuation were mainly cough in the ramipril groups
(47% of discontinuations) and unspecified patient request
in the placebo group (50%). Baseline demographic data
are shown in Table 1. Concomitant medication did not
differ between groups. The most frequently used cate-
gories of drugs were acetylsalicylic acid (approximately
87%), statins (45%), b-blockers (38%), glycerylnitrate
(36%), isosorbide-mononitrate (27%), and calcium-
channel blockers (19%). Concomitant diseases were
similar in the three groups. Around one-quarter of the
patients had a history of hypertension, approximately one
in 10 had diabetes, around half had undergone cardiac
surgery, and around half of the patients had a history of
myocardial infarction.
Baseline and study end data for the three main efficacy vari-
ables are shown in Table 2. There were no significant differ-
ences between the three groups in any of these variables.
It has been suggested that patients with coronary artery
disease who respond to an ACE inhibitor with a systolic
blood pressure reduction of 10 mmHg or more benefit the
most from such treatment in terms of exercise tolerance
[13]. Therefore, a prespecified aim of the study was to
investigate whether any improvements in the primary effi-
cacy variables were related to the systolic blood pressure
changes during the study. We examined whether the
changes from baseline to study end in duration of STD
and total ischaemic burden were related to the blood
pressure changes from baseline to the following time
points: the end of the titration period (after 1 week of ran-
domized treatment); 12 weeks of randomized treatment;
and study end. Ramipril patients who had a systolic blood
pressure reduction of 10 mmHg or more and ramipril
patients who had a blood pressure reduction of below
10 mmHg (including those with no fall or a blood pressure
increase) at the respective time points were compared
with all placebo patients. We also compared the two
ramipril patient categories with one another. The same
comparisons were performed using a systolic blood pres-
sure cutoff value of 20 mmHg. There were no significant
differences in any of these comparisons.
There were no differences between the treatment groups
in terms of adverse events or other safety data. At least
one adverse event during the double-blind study period
was reported by 58% of the patients in the ramipril 5 mg
group, by 56% in the ramipril 1.25 mg group and by 50%
in the placebo group (not significant). A total of 45 serious
adverse events were reported, with no between-group dif-
ferences in number or type of serious adverse events.
None of the serious adverse events were judged to be
related to the study drug. There were no deaths during the
study period.
Discussion
There were no differences in the primary efficacy variables
between the three treatment groups (ramipril 5 mg/day,
ramipril 1.25 mg/day and placebo) in terms of changes
over the 24 weeks from baseline to study end. Indeed,
there were no trends in favour of ramipril in any dose com-
pared with placebo in terms of myocardial ischaemia as
assessed by ambulatory electrocardiography. Ramipril
was well tolerated, and there were no significant differ-
ences in the frequency of adverse events between the
ramipril groups and placebo.
Available online http://cvm.controlled-trials.com/content/2/2/099
Table 1
Baseline demographics
Variable Ramipril 5 mg (n = 133) Ramipril 1.25 mg (n = 133) Placebo (n = 123)
Age (years [range]) 66 (47–80) 65 (32–79) 66 (39–78)
Female sex (%) 32 37 37
Height (cm [range]) 171 (150–192) 170 (150–190) 170 (150–186)
Weight (kg [range]) 76 (46–108) 75 (49–107) 75 (47–108)
Smoking status (%)
Never 31 28 29
Prior 52 50 53
Current 17 22 18What is ST-segment depression on ambulatory
electrocardiography?
STD on ambulatory electrocardiography is considered to
reflect myocardial ischaemia, but the mechanisms respon-
sible are not fully understood. STD probably reflects
myocardial ischaemia precipitated both by increased
cardiac work through static stenoses, and by increased
vascular tone and/or coronary spasm in dynamic stenoses.
Possible short-term anti-ischaemic effects of
angiotensin-converting enzyme inhibition
ACE inhibitor treatment may decrease myocardial
ischaemia by improving coronary blood flow and microcir-
culation. On a short-term basis, this may be caused by
improved endothelial function as a consequence of
decreased levels of angiotensin II, and increased levels of
bradykinin and NO [19]. In addition, the tendency toward
vascular spasm may be counteract by ACE inhibitors;
ACE expression and angiotensin II production are
increased in atherosclerotic tissue [20], and local ACE
inhibition may decrease oxidative stress and improve
endothelial function at the sites of plaques. That ACE
inhibitor treatment impacts on endothelial function is sup-
ported by the findings of prior studies. The Trial on
Reversing Endothelial Dysfunction (TREND) [21,22]
demonstrated an improvement in endothelial vasomotor
dysfunction in patients with ischaemic heart disease
treated with quinapril over 6 months, and it was indicated
that ACE inhibition increased microvascular coronary
blood flow. Moreover, in a study by Gasic et al [23], cilaza-
pril improved regional myocardial blood flow to the
ischaemic myocardium in patients with stable angina.
Angiotensin II facilitates the release of noradrenaline from
sympathetic nerve terminals [24], and ACE inhibitors have
been shown [25–27] to exert parasympathomimetic
effects, to improve baroreflex sensitivity in patients after
myocardial infarction [28] and to reduce sympathetic
vasomotor tone in hypertensive patients [29]. Conse-
quently, an ACE-inhibitor-induced reduction in sympa-
thetic activity due to decreased levels of angiotensin II
may, in the short term, contribute to a decrease in myocar-
dial ischaemia. However, how ACE inhibition modulates
sympathetic activity in humans is still controversial [30].
A haemodynamic effect due to decreased preload and
afterload resulting from ACE inhibitor-induced vasodilata-
tion may also contribute to an anti-ischaemic effect by
reducing cardiac work and oxygen consumption.
Possible long-term anti-ischaemic effects of
angiotensin-converting enzyme inhibition
An improved neurohormonal balance may, in the long
term, induce regression of structural myocardial changes,
such as myocardial fibrosis. Such an effect may be inde-
pendent of any haemodynamic effects and attributed to
inhibition of cardiac tissue ACE, as seen in experimental
studies [31]. Even a modest regression of fibrosis may
improve coronary vessel compliance, especially a reduc-
tion in perivascular fibrosis [32,33]. Such a change may
improve coronary reserve, which in particular might attenu-
ate postexercise ischaemia.
Several experimental [34–36] and clinical [37] studies have
shown that ACE inhibitors are able to inhibit the atheroscle-
rotic process. However, ACE inhibitors have shown little
success in preventing restenosis after angioplasty in
humans [38], and in the Quinapril Ischemic Event Trial
(QUIET) [6] treatment with quinapril after angioplasty failed
to reduce mortality and recurrence of angina pectoris in
comparison with placebo. An antiatherogenic effect of ACE
inhibition would most likely take quite some time to develop.
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Table 2
ST-segment analysis
Ramipril 5 mg Ramipril 1.25 mg Placebo
Variable Visit n Mean SD n Mean SD n Mean SD
STD duration (min) Baseline 133 361 443 133 393 468 123 426 467
1 month 123 319 463 120 326 473 113 406 480
Study end 117 332 480 116 367 493 113 318 418
Ischaemic burden Baseline 133 1428 3248 133 1571 3213 123 1387 2299
1 month 123 1309 2950 120 1302 2855 113 1366 2505
Study end 117 1276 2612 116 1467 3394 113 1101 2527
Maximum STD (mV) Baseline 133 0.23 0.09 133 0.24 0.10 123 0.26 0.11
1 month 123 0.18 0.12 121 0.20 0.13 113 0.22 0.12
Study end 118 0.22 0.15 116 0.22 0.13 113 0.23 0.14
There were no significant differences in the changes from baseline to study end between the ramipril groups and placebo. STD is defined as ST-
segment depression of ³0.1 mV. STD duration and ischaemic burden are given per 24 h. SD, standard deviation.Why was the study result neutral?
Too low doses of ramipril
There may be several reasons for the neutral study result.
The doses of ramipril might have been too low. The rec-
ommended dose in clinical practice is 5 mg twice a day or
10 mg once a daily (ie twice as much as the highest dose
and eight times the lower dose in the present study). Why
was such a low dose as 1.25 mg/day chosen? The reason
is that we wanted to test the hypothesis that a dose that
does not affect central haemodynamics would still
decrease myocardial ischaemia. This hypothesis was
based on findings in experimental [17] and clinical [18]
studies that suggested an antiremodelling effect of low,
nonantihypertensive doses of ramipril. This hypothesis was
clearly not supported by the results of the present study.
Inadequate method for detecting myocardial ischaemia
The method used might not have been relevant to the
study efficacy variables, although we have shown that
ambulatory electrocardiography has the same diagnostic
accuracy for myocardial ischaemia as does exercise elec-
trocardiography examination [39]. However, ambulatory
electrocardiography may overlook myocardial ischaemia in
patients who predominantly develop ischaemia with STD
at high exercise loads. Thus, if such patients benefit from a
real anti-ischaemic effect of ramipril, then very little or none
of that effect may be registered unless the patients
perform high-intensity exercise.
Influence of concomitant treatment
An interaction between acetylsalicylic acid and ACE
inhibitors may exist, although this is considered controver-
sial [40]. Because 87% of the patients studied were
treated with acetylsalicylic acid, it is possible that such an
interaction might have blunted any beneficial effect of
ramipril. Statins are known to improve endothelial function
[41]. In the present study, almost half of the patients were
being treated with a statin, and it may be that there is little
to gain by adding an ACE inhibitor to the regimen of such
patients.
There may be no anti-ischaemic effects of angiotensin-
converting enzyme inhibitors
Perhaps there are no true anti-ischaemic effects of ACE
inhibition. Indeed, it has been indicated [42] that ACE
inhibitors may not inhibit angiotensin II production in the
coronary circulation, and short-term ACE inhibition has
failed to reduce myocardial ischaemia [11,12]. Despite
clear haemodynamic effects, captopril had only marginal
anti-ischaemic effects, in monotherapy as well as com-
bined with isosorbide dinitrate [12]. However, true anti-
ischaemic effects have been indicated in patients with left
ventricular systolic dysfunction [9,10]. Therefore, an alter-
native explanation for the neutral finding of the present
study is that ACE inhibitors may not have anti-ischaemic
effects in patients with stable coronary artery disease and
preserved left ventricular systolic function. Although anti-
ischaemic effects of ACE inhibition have been indicated in
such patients [13–16], perindopril was shown to have a
significantly less pronounced anti-ischaemic effect in
patients with normal left ventricular systolic function than
in those with impaired ejection fraction [43].
Effects on clinical end-points are not equivalent to 
anti-ischaemic effects
The beneficial effects of ACE inhibition on clinical end-
points related to myocardial ischaemia that have been
demonstrated in previous studies [6–8,44,45] do not rep-
resent evidence for a direct anti-ischaemic effect, and
might have an alternative explanation. The mechanisms
that underlie ischaemic events include plaque destabiliza-
tion, among others, whereas angina is caused by an imbal-
ance between the oxygen supply and demand. An ACE
inhibitor need not equally affect these parameters. Indeed,
captopril treatment for 1 year after a myocardial infarction
significantly reduced the incidence of ischaemia-related
clinical events, but had no anti-ischaemic effects during
exercise testing [46]. Consequently, the results of clinical
end-point trials do not contradict the present findings.
Other reasons
The study duration may have been too short to demon-
strate any beneficial effects of ACE inhibition. However, as
mentioned above, some of the mechanisms by which ACE
inhibition may counteract myocardial ischaemia might be
expected to develop within the time frame of the present
study. Indeed, the benefits in the TREND study were
demonstrated within 6 months [21,22].
Although we made every effort to include patients with
coronary artery disease, the patients selected for the
present study might not all have had true myocardial
ischaemia. It is well known that ‘unspecific’ STD may be
the result of left ventricular hypertrophy. This is especially
likely if STD occurs during most of the 24-h monitoring
period. Some of the patients in this study might have been
such patients, and anti-ischaemic effects of ramipril
cannot be anticipated in these patients. On the other
hand, it is likely that STD in such patients is due to
endothelial dysfunction, which should be at least partly
reversible by ACE inhibition [32].
Did the present study show any beneficial effects of
ramipril?
A random subset of 98 of the patients in the present study
was examined by echocardiography/Doppler at baseline
and study end. There was a significant beneficial effect of
ramipril on resting left ventricular function and on postexer-
cise left ventricular filling, as compared with patients
treated with placebo [47]. However, these effects may not
necessarily have been caused by anti-ischaemic mecha-
nisms of the ramipril intervention. Further analyses have
Available online http://cvm.controlled-trials.com/content/2/2/099
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showed a clear blood pressure reduction experienced
improved left ventricular function at rest and after exercise,
whereas those who did not respond to the ramipril inter-
vention by a clear blood pressure reduction did not
improve (Willenheimer R, et al, unpublished data). This
relation was independent of the ramipril dose. The obser-
vation might be explained by a more pronounced reduc-
tion in afterload among patients with a clear blood
pressure response, and need not affect myocardial
ischaemia, as indicated previously [12].
Conclusion
Six months of treatment with ramipril in patients with stable
ischaemic heart disease and preserved left ventricular sys-
tolic function did not exhibit any favourable effects on
myocardial ischaemia, as assessed by ambulatory electro-
cardiography. There are a number of possible explanations
for this neutral study result, including too low a dose of
ramipril, patient selection, a suboptimal method for the
detection of an anti-ischaemic effect, and insufficient study
duration. However, it is also possible that ACE inhibitors
have no direct anti-ischaemic effects, despite their well-
documented ability to protect against ischaemia-related
clinical events. Future studies will have to investigate
further whether ACE inhibitors have true anti-ischaemic
effects in patients with stable ischaemic heart disease and
preserved left ventricular systolic function.
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